In the cixutumumab trial, tumor levels of IGF-1, IGF-2, and IGF-1R were evaluated by immunohistochemistry, but there was no correlation between expression of these three proteins and response to cixutumumab treatment (94). The gene discussed is IGF1; the disease is neoplasm.